View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
July 15, 2019updated 12 Jul 2022 12:28pm

Ascentage beings dosing in Phase I trial of APG-2575

Ascentage Pharma has started dosing patients in a Phase I clinical trial of its Bcl-2 selective inhibitor APG-2575 to treat hematologic malignancies in China.

Ascentage Pharma has started dosing patients in a Phase I clinical trial of its Bcl-2 selective inhibitor APG-2575 to treat hematologic malignancies in China.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Formulated for oral administration, APG-2575 has been designed to specifically block Bcl-2 to restore the normal apoptosis process in cancer cells.

The Phase I trial is intended to evaluate the safety and tolerance of the compound in patients suffering from hematologic malignancies. The trial will also aim to determine the maximal tolerated dose (MTD) or recommended Phase II dose (RP2D).

It will enrol subjects with acute myelogenous leukemia (AML) or non-Hodgkin’s lymphoma (NHL).

The first participant was dosed at the Institute of Hematology, Blood Disease Hospital of Chinese Academy of Medical Sciences during the initial dose-escalation part.

Ascentage Pharma chairman and CEO Dr Dajun Yang said: “APG-2575 is a key product in our development pipeline of apoptosis. Initiating the clinical trial in China represents a new step in our global clinical development. We believe that APG-2575 may provide more therapy options to patients with blood diseases.”

APG-2575 is also being evaluated as a monotherapy in an ongoing multi-centre Phase I dose-escalation trial across multiple sites in the US and Australia.

This trial has been designed for people with various types of blood cancer, including AML, NHL, chronic lymphocytic leukaemia (CLL) and multiple myeloma (MM).

Currently, the study has completed four dose cohorts in the US and Australia.

Preliminary trial data showed that APG-2575 was well tolerated with a favourable safety profile. The therapeutic also showed promising anti-tumour activity in relapsed / refractory CLL.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena